Retatrutide explained
Published research context on the compound at the centre of recent metabolic literature. Reference information only — never a product claim.
- What is retatrutide?
- What does triple agonist mean?
- What do GLP-1, GIP and glucagon do?
- What is an incretin?
- What do incretin hormones do?
- What is the difference between single, dual and triple agonists?
- What is peptide half-life?
- What is the difference between half-life and duration of action?
- What is a phase 2 clinical trial?
- Why is retatrutide sold as 10 mg?
What is retatrutide?
Retatrutide is a synthetic 39-amino-acid peptide that acts as an agonist at three receptors: GLP-1, GIP and glucagon. It is the most-studied of the so-called next-generation incretin compounds in recent metabolic research literature. It is supplied here as a lyophilized powder for laboratory research use only.
What does triple agonist mean?
A triple agonist is a single molecule that activates three different receptors. Retatrutide is engineered so that one peptide sequence binds and activates GLP-1, GIP and glucagon receptors, rather than requiring three separate compounds. The design goal is combined signalling from one molecule.
What do GLP-1, GIP and glucagon do?
All three are signalling pathways involved in metabolic regulation. GLP-1 and GIP are incretins, released from the gut in response to food, and influence insulin signalling. Glucagon acts largely on the liver and on energy expenditure. Compounds are described by which of these receptors they activate.
What is an incretin?
An incretin is a gut hormone released after eating that influences insulin signalling. GLP-1 and GIP are the two principal incretins in humans. The term appears constantly in metabolic research literature because a large family of studied compounds works by mimicking incretin activity at their receptors.
What do incretin hormones do?
Incretins are released from the gut in response to food and signal to the pancreas, influencing insulin release in a glucose-dependent way. They also affect gastric emptying and satiety signalling. This is why the incretin pathway became such a heavily studied target in metabolic research.
What is the difference between single, dual and triple agonists?
The number refers to how many receptors one molecule activates. Semaglutide is a single agonist, acting at GLP-1 alone. Tirzepatide is a dual agonist, adding GIP. Retatrutide is a triple agonist, adding glucagon. Each added receptor changes the signalling profile studied in the published literature.
What is peptide half-life?
Half-life is the time taken for the concentration of a compound to fall by half. It is a property of the molecule and the system it is in, not of the vial. Longer half-lives mean slower clearance, which is why half-life is reported so consistently in pharmacokinetic literature.
What is the difference between half-life and duration of action?
Half-life measures how fast a compound is cleared. Duration of action measures how long its effect persists. They are related but not the same: a compound can be largely cleared while a downstream effect continues, or be present yet no longer producing a measurable response.
What is a phase 2 clinical trial?
A phase 2 trial tests a compound in a few hundred participants, after phase 1 has examined safety in a small group. It looks for evidence of effect and further safety signals, and informs dose selection for the much larger phase 3 trials that follow. Phase 2 results are preliminary by design.
Why is retatrutide sold as 10 mg?
Because a lyophilized peptide begins to degrade once it is reconstituted. A 10 mg vial is sized so a reconstituted batch is used while still within its documented stability window, rather than sitting in solution for months. It is a potency decision rather than a limitation on quantity.